Biomass extracts for skin applications
By combining the prebiotic compositions that react with the ionic polymer catalyst and are isolated with the dermatological carrier, the problem that traditional prebiotic agents are difficult to achieve the skin microbiome is solved, and effective prebiotic effects for local skin applications are achieved. Immune stimulation.
Patent Information
- Application Number
- CN202380026009.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-02-03
- Filing Date
- 2023-02-02
- Publication Date
- 2024-11-22
AI Technical Summary
It is difficult for the prior art to effectively utilize prebiotic agents to improve skin health and appearance, and traditional prebiotic agents are mainly delivered by oral means, and have failed to effectively achieve the best effect of the skin microbiota.
By providing a method for producing a prebiotic composition, including providing a biomass, determining its components, performing hot water pretreatment, removing lipids and proteins, and reacting with an ionic polymer catalyst, degrading the biomass to produce a liquid phase and solid phase, separate prebiotic compositions in the liquid phase and combine them with a dermatologically acceptable carrier for topical skin applications.
Effective delivery of local cosmetic compositions is achieved, the growth of skin symbiotic bacteria is regulated, microbial disorders are prevented, immune skin system is stimulated, and skin health and appearance are improved.
Smart Images

Figure BDA0005031299100000021 
Figure BDA0005031299100000022 
Figure BDA0005031299100000031
Abstract
Description
Technical Field
[0001] The present invention relates to compositions having prebiotic and antimicrobial properties and their use for dermocosmetic purposes, such as regeneration and protection of the skin. Background Art
[0002] Mammalian skin is considered one of the largest organs in the body, especially the organ with the largest surface area. The skin forms the first line of defense against microorganisms that can enter the body through the air, water, food, or materials that come into contact with the body. When the skin or the whole body of the body becomes infected, the traditional approach to addressing this hygiene issue is to treat the skin / body with antimicrobial actives that reduce or kill the bacteria. Recent studies have shown that many bacteria that are constantly present on the skin (called skin commensal bacteria) do not actually cause infection, but rather, are beneficial bacteria that protect the skin from disease-causing pathogens. Therefore, there is a trend away from treating the skin with broad-spectrum antimicrobial actives to kill all microorganisms present on the skin (or any other part of the body) as a means of treating infections. Instead, this approach prefers to target or selectively inhibit / kill desired microorganisms to exclude skin commensal microorganisms and / or to enhance the number and function of skin commensal bacteria through the use of prebiotics.
[0003] The health and beauty benefits of providing a healthy, balanced skin microbiome have only recently been better understood. As a result, only a limited number of suitable prebiotic agents have been identified for use on the skin. Furthermore, traditional prebiotic agents are typically administered orally, for example as part of a nutritional supplement regimen. While oral ingestion may be suitable for delivering prebiotic agents to the gastrointestinal tract, it may not be the best way to deliver prebiotics to the microbiome on the skin.
[0004] Therefore, there is a need to improve the health and / or appearance of human skin by providing compositions that exhibit prebiotic activity on one or more skin commensal microorganisms. At the same time, there is a need to control unwanted microbial activity. Summary of the invention
[0005] One aspect of the present invention provides a method for producing a prebiotic composition, the method comprising the following steps:
[0006] a) providing biomass;
[0007] b) optionally, determining the content of lipids, proteins and / or carbohydrates in the biomass;
[0008] c) optionally, pretreating the biomass, wherein the optional pretreatment is hot water pretreatment at about 90° C.;
[0009] d) optionally, removing lipids and / or proteins from the biomass;
[0010] e) contacting the biomass with a catalyst in the presence of water and / or an organic solvent to form a reaction mixture, wherein the catalyst is an ionic polymer or a combination of ionic polymers, an ionic polymer network, a solid-supported ionic polymer, and / or a polymer membrane doped with an ionic polymer;
[0011] f) heating the reaction mixture to 100° C. to 150° C. and degrading the biomass in the reaction mixture to produce a liquid phase and a solid phase, wherein the liquid phase comprises the prebiotic composition and the solid phase comprises residual biomass;
[0012] g) cooling the reaction mixture to room temperature;
[0013] h) separating at least a portion of the liquid phase from the solid phase;
[0014] i) optionally, adding one or more compounds selected from bentonite, charcoal, zeolite, amorphous silica and / or ion exchange solvents to the separated liquid phase; and
[0015] j) recovering the prebiotic composition from the separated liquid phase;
[0016] Wherein the ionic polymer (IP) is composed of monomers of formula I
[0017]
[0018] or composed of a first monomer of formula I and at least one second monomer
[0019]
[0020] The second monomer is selected from:
[0021]
[0022] in
[0023] n and m are independently selected from 1, 2, 3, 4, 5, 6;
[0024] z and w are independently selected from 0, 1, 2, 3;
[0025] Z1, Z2 and Z3 are each independently selected from the following cations:
[0026]
[0027] R1, R2, R3, R4, R5, R6 and R7 are each independently selected from a bond, H, C1-C6 alkyl, C1-C6 allyl, -CH2-(CH2)pO-(CH2)q-CH3, C1-C6 alkoxy, C1-C6 alkoxyalkyl, benzyl, -SO3H, -(CH2)q-SO3H, provided that two of R1, R2, R3, R4, R5, R6 and R7 are each a bond;
[0028] p and q are independently selected from 0, 1, 2, 3, 4, 5, 6;
[0029] L is an optional linker and, if present, each occurrence of L is independently selected from H, substituted or unsubstituted C1-C 20 Alkylene, C1-C 20 Alkenylene, C1-C 20 Alkyne and substituted or unsubstituted C5-C 10 Aryl, wherein the substituent is selected from H, -SO3H, -COOH, -[P(=O)(OH)2], -O-SO3H, -O-COOH, -O-[P(=O)(OH)2];
[0030] A is an optional acidic group and, if present, is independently selected at each occurrence from H, -SO3H, -COOH, -[P(=O)(OH)2], -O-SO3H, -O-COOH, -O-[P(=O)(OH)2], -CH2-COOH, provided that when z and w are 0, A is present in Formula IV;
[0031] X - Selected from F - , Cl - Br - ,I - 、ClO4 - 、BF4 - PF6 - 、AsF6 - 、SbF6 - 、NO2 - 、NO3 - 、HSO4 - 、SO4 2- PO4 3- 、HPO4 2- CF3CO2 - CF3CO3 - 、CO3 2- CF3SO3 - 、C1-C6 carboxylate、CN - 、SCN - 、OCN - 、CNO- 、N3 - , tosylate, methanesulfonate, trifluoromethanesulfonate, trifluoroethanesulfonate, bis-trifluoromethanesulfonamido, docusate, ditoluenesulfonate;
[0032] Ra is C1-C 24 alkyl;
[0033] Rb and Rc are each independently selected from H and CH3, or are absent;
[0034] Rd is C1-C 24 Alkylene or C1-C 24 Alkyl, optionally C1-C 24 Alkyl substitution;
[0035] Re and Rf are each independently C1-C 24 alkyl;
[0036] Y is N or O, provided that when Y is O, Rc is absent;
[0037] R is selected from C1-C 24 Alkyl and C5-C 10 Aryl, or absent.
[0038] wherein the ionic polymer network comprises one or more ionic polymers (IPs) that are cross-linked;
[0039] wherein the solid support has at least one surface comprising the one or more ionic polymers (IP) or the ionic polymer network;
[0040] wherein the polymer membrane incorporates the one or more ionic polymers (IP) or the ionic polymer network.
[0041] Another aspect of the present invention provides a prebiotic composition obtained by the method of the present invention.
[0042] Another aspect of the present invention provides a topical cosmetic composition comprising:
[0043] An effective amount of the prebiotic composition of the present invention, and
[0044] - At least one dermatologically acceptable carrier.
[0045] Another aspect of the invention provides the use of a prebiotic composition of the invention or a topical composition of the invention for the non-therapeutic treatment of the skin.
[0046] Another aspect of the invention provides the use of a prebiotic composition of the invention or a topical composition of the invention for modulating the growth of at least one commensal bacteria of the skin, the method comprising applying to the skin an effective amount of a prebiotic composition of the invention or a topical composition of the invention.
[0047] Another aspect of the present invention provides the use of the prebiotic composition of the present invention or the topical composition of the present invention for preventing dysbiosis on the external surface of the human body or animal body.
[0048] Another aspect of the invention provides the use of a prebiotic composition of the invention or a topical composition of the invention for stimulating the immune skin system. BRIEF DESCRIPTION OF THE DRAWINGS
[0049] Figure 1 Gene expression by qRT-PCR is shown: Inhibitory studies against S. aureus.
[0050] Figure 2 Gene expression after 2 days of prebiotic study on S. epidermidis is shown. Specific implementation plan
[0051] The entire contents of all publications, patent applications, patents and other references mentioned herein are incorporated herein by reference. The publications and applications discussed herein are provided only because they are disclosed prior to the filing date of the present application. Nothing herein should be construed as an admission that the present invention is not entitled to precede these publications by virtue of prior invention. In addition, the materials, methods and examples are illustrative only and are not intended to be limiting.
[0052] In the event of a conflict, the present specification including definitions will prevail. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art to which the subject matter of this document belongs. As used herein, the following definitions are provided to facilitate understanding of the present invention.
[0053] The term "comprising" is generally used in an inclusive sense, that is, one or more features or components are allowed to be present. As used in the specification and claims, the term "comprising" may include similar embodiments described with "consisting of" and / or "consisting essentially of".
[0054] As used in the specification and claims, the singular forms ("a," "an," and "the") include plural referents unless the context clearly dictates otherwise.
[0055] As used in the specification and claims, the term "and / or" used herein in phrases such as "A and / or B" is intended to include "A and B", "A or B", "A", and "B".
[0056] "Cosmetic composition" means a composition suitable for topical application to mammalian (preferably human) skin and / or other keratinous tissue (such as hair and nails) for the purpose of improving the condition and / or appearance of the skin or keratinous tissue, or otherwise providing a skin care benefit. Topical refers to the surface of the skin or other keratinous tissue. Cosmetic compositions include makeup, nail or skin care products of any color. "Skin care" means regulating and / or improving the condition of the skin. Some non-limiting examples of skin care benefits and improvements in skin condition and / or appearance include improving the appearance and / or feel of the skin by providing a smoother, more even look and / or feel; increasing the thickness of one or more layers of the skin; improving the elasticity or resiliency of the skin; improving the firmness of the skin; and reducing the oiliness, glow, and / or dull appearance of the skin, improving the hydration or moisturization of the skin, improving the appearance of fine lines and / or wrinkles, improving skin texture or smoothness, improving skin flaking or scaling, plumping the skin, improving skin barrier properties, improving skin tone, reducing the appearance of redness or skin spots, and / or improving the brightness, gloss, or translucency of the skin. Some non-limiting examples of cosmetic compositions include products that leave color on the face, such as foundation, mascara, concealer, eyeliner, eyebrow color, eye shadow, blush, lipstick, lip balm, face powder, solid emulsion-type pressed powder, etc. "Skin care products" include, but are not limited to, skin creams, moisturizers, lotions, and shower gels.
[0057] "Dermatologically acceptable carrier" refers to a carrier that can be topically applied to the skin or keratinous tissue. Dermatologically acceptable carriers can be in a variety of forms, such as simple solutions (water-based or oil-based), solid forms (gels or sticks), and emulsions (water-in-oil or oil-in-water).
[0058] An "effective amount" refers to a sufficient amount of a particular component / composition to have a particular property under particular conditions. For example, an effective amount of a prebiotic composition is an amount sufficient to cause a desired increase in metabolite levels and / or bacterial counts of one or more selected microorganisms in vitro and / or in vivo.
[0059] "Prebiotic" refers to any substance or combination of substances that can be used as a nutrient by a selected microorganism (e.g., a skin commensal microorganism), can induce the growth and / or activity of a selected microorganism, can induce the replication of a selected microorganism, can be used as an energy source by a selected microorganism, and / or can be used by a selected microorganism to produce biomolecules (i.e., RNA, DNA, and proteins). Non-limiting examples of prebiotics include mucopolysaccharides, oligosaccharides such as galacto-oligosaccharides ("GOS"), polysaccharides, amino acids, vitamins, nutrient precursors, harvested metabolites of biological organisms, lipids, and proteins.
[0060] "Replication" refers to the division of a microorganism into daughter cells (eg, by mitosis or binary fission).
[0061] "Skin" refers to one or more of the epidermis, dermis and hypodermis (i.e., subcutaneous tissue), hair follicles, hair roots, hair follicle bulbs, ventral epithelial layer (lectulus) of nail beds, sebaceous glands, and sweat glands (exocrine glands and apocrine glands). Skin is mammalian skin, preferably human skin. In some embodiments, skin is the outer surface of a human or animal body.
[0062] "Skin commensal microorganisms" or "skin commensal bacteria" or "commensal bacteria" refer to prokaryotes and eukaryotes that can colonize (i.e., live and reproduce on) or temporarily reside on human skin in vitro and / or in vivo. Commensal bacteria act on the host's immune system to induce a protective response to prevent colonization and invasion by pathogens.
[0063] "Topical" and variations thereof refer to compositions intended for application directly to the external surface of the skin or other keratinous tissue.
[0064] Unless otherwise specified, the term "microbiome" refers to the collective genomes of microorganisms (including bacteria, bacteriophages, fungi, protozoa, and viruses) living in and on the human body.
[0065] An "allyl" group is a substituent having the formula H2C=CH-CH2R, where R is the remainder of the molecule.
[0066] The term "monomer" refers to a molecule capable of being polymerized or copolymerized to contribute a building block to the basic structure of a macromolecule (polymer).
[0067] As used herein, "crosslinking" refers to the connection of two or more monomers, oligomers or longer polymer chains through a bridge of a crosslinking agent such as an element, a molecular group, a compound or another oligomer or polymer. Crosslinking can form a polymer network (which can be two-dimensional or three-dimensional) in which polymer subunits are interconnected with a variety of crosslinking agents and have no free ends. Crosslinking can occur when exposed to a stimulus (such as heat or light). Therefore, some crosslinking processes occur when the temperature is increased, while some crosslinking processes can also occur at room temperature or lower temperatures. As the crosslinking density increases, the properties of the material can be converted from thermoplastic to thermosetting.
[0068] As used herein, "phenolic compounds" are a group of small molecules characterized in that their structure has at least one phenolic unit.
[0069] One aspect of the present invention provides a method for hydrolyzing biomass into a prebiotic composition having excellent antimicrobial and prebiotic properties.
[0070] In one embodiment, the present invention provides a method for producing a prebiotic composition from biomass, the method comprising the steps of:
[0071] a) providing biomass;
[0072] b) optionally, determining the content of lipids, proteins and / or carbohydrates in the biomass;
[0073] c) optionally, pretreating the biomass, wherein the optional pretreatment is hot water pretreatment at about 90° C.;
[0074] d) optionally, removing lipids and / or proteins from the biomass;
[0075] e) contacting the biomass with a catalyst in the presence of water and / or an organic solvent to form a reaction mixture, wherein the catalyst is an ionic polymer or a combination of ionic polymers, an ionic polymer network, a solid supported ionic polymer and / or a polymer membrane doped with an ionic polymer;
[0076] f) heating the reaction mixture to 100° C. to 150° C. and degrading the biomass in the reaction mixture to produce a liquid phase and a solid phase, wherein the liquid phase comprises the prebiotic composition and the solid phase comprises residual biomass;
[0077] g) cooling the reaction mixture to room temperature;
[0078] h) separating at least a portion of the liquid phase from the solid phase;
[0079] i) optionally, adding one or more compounds selected from bentonite, charcoal, zeolite, amorphous silica and / or ion exchange solvents to the separated liquid phase; and
[0080] j) recovering said prebiotic composition from said separated liquid phase.
[0081] In one embodiment, step e) contacting the biomass with a catalyst to form a reaction mixture comprises: adding water or a suitable organic solvent and an effective amount of a catalyst to the biomass to form a reaction mixture, wherein the catalyst is an ionic polymer of the present invention or a combination of ionic polymers of the present invention, an ionic polymer network of the present invention, a membrane doped with an ionic polymer of the present invention and / or a solid supported ionic polymer of the present invention; the degradation step f) comprises heating the reaction mixture of step e) for an appropriate time, followed by cooling to room temperature (typically 20°C to 25°C).
[0082] In some embodiments of the method for producing a prebiotic composition from biomass, the method further comprises applying a pressure of N2 or CO2 during the degradation step f). The pressure may range from 20 bar to 300 bar, preferably from 20 bar to 150 bar.
[0083] In some embodiments of the method of producing a prebiotic composition from biomass, step i) is performed, ie, this step is not optional.
[0084] As used herein, the term "biomass" refers to living or dead biological material that can be used in the method of producing the prebiotic composition of the present invention. In some embodiments, the biomass is selected from: spent yeast slurry, spent barley, brewer's spent grains, pellets, nut cakes or (cattle feed) cakes (cattle cake); crops or crop residues: corn, soybeans, sorghum, oats, barley, copra, husks, skins or husks, sugar beet waste; peeled products; fish meal; meat and bone meal; molasses; oil cakes and press cakes; oligosaccharides; preserved forage plants: silage; seaweed; seeds and grains prepared whole or by crushing, grinding, etc.; germinated grains and legumes; yeast extract. Preferably, the biomass is yeast slurry or brewer's spent grains. Most preferably, the biomass is brewer's spent grains. The term "brewer's spent grains (BSG)" is a food waste that is a by-product of the brewing industry and is obtained as the main solid residue after the wort is produced in the brewing process. The term "yeast slurry" is often used in the brewing industry to describe a paste-like mixture of yeast and liquid.
[0085] Optionally, before any use, the content of carbohydrates and / or lipids in the biomass is determined based on standard methods. The Folch method (Folch J, Lees M, Stanley, GHS, 1957, 226, 497–509) involving a mixture of methanol, chloroform and water (2: 1: 0.8, volume / volume / volume) can be used to determine / extract lipids, followed by phase separation. Carbohydrate determination is performed according to the NREL protocol, for example, "Determination of structural carbohydrates and lignin in biomass". For example, 1 ml of 72% sulfuric acid is added to 100 mg of biomass. The slurry is stirred at 30 ° C for 1 hour, and then 28 ml of deionized water is added. The mixture is autoclaved at 120 ° C for 1 hour, cooled to room temperature, and used for sugar analysis by HPLC and acid-soluble lignin determination using ultraviolet spectrophotometry at a wavelength of 205 nm. The same hydrolyzate is used for protein analysis according to the Bradford protein assay. The acid hydrolyzed residue was washed with 100 mL of water and then dried at 105°C to determine Klason lignin.
[0086] The optional pretreatment of the biomass used in the methods described herein uses one or more of the following methods: washing, solvent extraction, solvent swelling, crushing, grinding, steam pretreatment, steam explosion pretreatment (explosive steam pre-treatment), dilute acid pretreatment, hot water pretreatment (about 90° C.), alkali pretreatment, lime pretreatment, wet oxidation, wet explosion, ammonia fiber explosion, organic solvent pretreatment, biological pretreatment, ammonia percolation, ultrasound, electroporation, microwave, supercritical CO2, supercritical H2O, ozone and gamma radiation. The optional pretreatment of biomass includes, for example, grinding biomass. In order to overcome the obstacle that the reaction rate is limited by surface reaction and mass transfer, it is strongly recommended to pretreat biomass by ball milling, which will reduce the crystallinity and increase the specific surface area of cellulose materials. According to the mechanical ball milling carried out on biomass, the structural particle size is reduced, the degree of polymerization of cellulose is reduced and the amorphous content of cellulose is increased.
[0087] In one embodiment of the method for producing a prebiotic composition of the present invention, the optional biomass pretreatment (step c) comprises hot water pretreatment of the biomass at about 90°C for 30 minutes to 2 hours, preferably 1 hour, followed by cooling to room temperature (20°C-25°C) and filtering to obtain a solid phase (i.e., pretreated biomass) to be used in step e).
[0088] The optional removal of lipids and / or proteins from the biomass used in the methods described herein provides a biomass richer in fiber products for further degradation according to step f). The removal of lipids is carried out by methods known in the art, such as mechanical pressing, organic solvents or supercritical CO2. The removal of proteins is carried out by methods known in the art, such as enzymes, alcohols, water with salts and / or surfactants, or extrusion.
[0089] Some ionic polymers used in the method of producing a prebiotic composition from biomass of the present invention are composed of anions and a polymer backbone containing cations as disclosed in WO 2019 / 058270 A1 (the entire contents of which are incorporated herein by reference). Specifically, the ionic polymer (IP) used in the method of producing a prebiotic composition from biomass of the present invention is composed of a monomer of formula I:
[0090]
[0091] or composed of a first monomer of formula I and at least one second monomer
[0092]
[0093] The second monomer is selected from
[0094]
[0095]
[0096] in
[0097] n and m are independently selected from 1, 2, 3, 4, 5, 6; preferably, n and m are independently selected from 1, 2, 3; most preferably, n is 2 and m is 1 or 2.
[0098] z and w are independently selected from 0, 1, 2, 3; preferably, z and w are independently selected from 0 and 1; most preferably, z and w are 0 or 1.
[0099] Z1, Z2 and Z3 are each independently selected from the following cations:
[0100]
[0101] Preferably, Z1, Z2 and Z3 are each independently selected from the following cations:
[0102]
[0103] Most preferably, Z1, Z2 and Z3 are each independently selected from the following cations:
[0104]
[0105] R1, R2, R3, R4, R5, R6 and R7 are each independently selected from a bond, H, C1-C6 alkyl, C1-C6 allyl, -CH2-(CH2)pO-(CH2)q-CH3, C1-C6 alkoxy, C1-C6 alkoxyalkyl, benzyl, -SO3H, -(CH2)q-SO3H, provided that two of R1, R2, R3, R4, R5, R6 and R7 are each bond; preferably, R1, R2, R3, R4, R5, R6 and R7 are each independently selected from a bond, H, C1-C6 alkyl, provided that two of R1, R2, R3, R4, R5, R6 and R7 are each a bond; most preferably, R1, R2, R3, R4, R5, R6 and R7 are each independently selected from a bond and H, provided that two of R1, R2, R3, R4, R5, R6 and R7 are each a bond;
[0106] p and q are independently selected from 0, 1, 2, 3, 4, 5, 6;
[0107] L is an optional linker and, if present, each occurrence of L is independently selected from H, substituted or unsubstituted C1-C 20 Alkylene, C1-C 20 Alkenylene, C1-C 20 Alkyne and substituted or unsubstituted C5-C 10 Aryl, wherein the substituents are selected from H, -SO3H, -COOH, -[P(=O)(OH)2], -O-SO3H, -O-COOH, -O-[P(=O)(OH)2], preferably, L is absent;
[0108] A is an optional acidic group, and if A is present, it is independently selected at each occurrence from H, -SO3H, -COOH, -[P(=O)(OH)2], -O-SO3H, -O-COOH, -O-[P(=O)(OH)2], -CH2-COOH, provided that when z and w are 0, A is present in formula IV; preferably, if A is present, it is independently selected at each occurrence from H, -SO3H, -COOH, -O-COOH, -CH2-COOH, provided that when z and w are 0, A is present in formula IV; most preferably, A is absent, or if A is present, it is independently selected at each occurrence from H, -COOH, -CH2-COOH, provided that when z and w are 0, A is present in formula IV;
[0109] X - Selected from F - , Cl - Br - ,I - 、ClO4 -、BF4 - PF6 - 、AsF6 - 、SbF6 - 、NO2 - 、NO3 - 、HSO4 - 、SO4 2- PO4 3- 、HPO4 2- CF3CO2 - CF3CO3 - 、CO3 2- CF3SO3 - 、C1-C6 carboxylate、CN - 、SCN - 、OCN - 、CNO - 、N3 - , toluenesulfonate, mesylate, trifluoromethanesulfonate, trifluoroethanesulfonate, di-trifluoromethanesulfonylamino, docusate, ditoluenesulfonate; preferably, X - Selected from F - , Cl - 、HSO4 - 、SO4 2- PO4 3- 、HPO4 2- CF3CO2 - CF3CO3 - CF3SO3 - Most preferably, X - Selected from Cl - 、HSO4 - 、SO4 2- CF3SO3 - .
[0110] Ra is C1-C 24 alkyl;
[0111] Rb and Rc are each independently selected from H and CH3, or are absent, preferably, Rc is absent;
[0112] Rd is C1-C 24 Alkylene or C1-C 24 Alkyl, optionally C1-C 24 Alkyl substituted, preferably, Rd is C1-C2 alkylene or C1-C2 alkyl or C1-C3 alkyl;
[0113] Re and Rf are each independently C1-C 24 Alkyl, preferably CH3;
[0114] Y is N or O, provided that when Y is O, Rc is absent;
[0115] R is selected from C1-C 24 Alkyl and C5-C 10 Aryl, or absent, preferably, R is CH3.
[0116] In the context of the present invention, the feature "A is an optional acidic group" means that A is an optional group, ie A may be present or absent, and is preferably an acidic group.
[0117] In some embodiments of the method, the second monomer of Formula VI of the ionic polymer (IP) is
[0118]
[0119] In some embodiments of the method, the second monomer of Formula VI of the ionic polymer (IP) is
[0120]
[0121] In some embodiments of the method, the (first) monomer of formula I of the ionic polymer (IP) is
[0122]
[0123] In some embodiments of the ionic polymers of the present methods, Z1 and Z2 are the same (identical). In other embodiments, Z1 and Z2 are different.
[0124] In some embodiments of the ionic polymers of the present methods, when Z1 and Z2 are Where R2 and R5 are a bond and R1, R3 and R4 are H, n is not 4.
[0125] In other embodiments of the ionic polymers of the present invention, when Z1 and Z2 are Wherein R2 and R5 are a bond and n is 4, at least one of R1, R3 and R4 is not H.
[0126] In some preferred embodiments of the ionic polymer of the present method, the C1-C6 carboxylate is selected from the group consisting of formate, acetate, propionate, butyrate, hexanoate, maleate, fumarate, oxalate, lactate, pyruvate.
[0127] The ratio between the different monomers in the ionic polymer of the present invention comprising the first monomer and the second monomer can be any suitable ratio and can vary depending on the biomass to be treated. In some embodiments, the first monomer and the second monomer are present in a ratio of 1:1 or 4:1. In some other embodiments, the ratio between the first monomer and the second monomer used in the methods described herein ranges from 4:1 to 1:4.
[0128] According to some embodiments of the method of the present invention, the monomer according to formula I is selected from:
[0129]
[0130] According to a further embodiment of the process according to the invention, the monomer according to formula I is selected from
[0131]
[0132] According to some embodiments of the method of the present invention, the monomer according to formula II is
[0133]
[0134] According to some embodiments, the methods of the present invention provide an ionic polymer selected from the group consisting of:
[0135]
[0136]
[0137]
[0138] x and y are each independently selected from integers of 1 to 1000; preferably 1 to 500 or 1 to 200; more preferably 1 to 100 or 1 to 50;
[0139] According to some embodiments, the methods of the present invention provide an ionic polymer selected from the group consisting of:
[0140]
[0141]
[0142] x and y are each independently selected from integers of 1 to 1000; preferably 1 to 500 or 1 to 200; more preferably 1 to 100 or 1 to 50;
[0143] According to an embodiment of the method of the present invention, the ionic polymer is
[0144]
[0145] According to another embodiment of the method of the present invention, the ionic polymer (IP-A5) is composed of a monomer of the following formula (I) and a monomer of the following formula VI:
[0146]
[0147] According to another embodiment of the method of the present invention, the ionic polymer (IP-A6) is composed of a monomer of the following formula (I) and a monomer of the following formula (VI):
[0148]
[0149] In some embodiments of the method for producing a prebiotic composition, the organic solvent is selected from alcohols (such as methanol, ethanol, butanol, ethylene glycol, etc., preferably ethanol), ethers (such as dimethoxyethane, diethylene glycol dimethyl ether, butyl methyl ether, etc.), ketones (such as methyl isobutyl ketone, N-methyl-2-pyrrolidone, etc.), deep eutectic solvents (such as glycerol, choline chloride, caprylic acid, tetrabutylammonium chloride, poly (ethylene glycol), choline chloride, lactic acid, glycine).
[0150] In some embodiments of the methods of the present invention, the prebiotic composition can be recovered by any technique known in the art (e.g., filtration, centrifugation, or gravity sedimentation). After recovery, the prebiotic composition can be used in liquid form or concentrated or dried into a powder form for use.
[0151] The effective amount of the ionic polymer of the present invention or a combination thereof used in the methods described herein can depend on several factors, including, for example, the type of biomass, the amount of biomass, the content of proteins, carbohydrates and / or lipids in the biomass, the type and number of pretreatments applied to the biomass, and the reaction conditions (e.g., temperature and time). An effective amount of the ionic polymer of the present invention refers to an amount sufficient to degrade the biomass into a prebiotic composition of the present invention. In some embodiments, the effective amount of the ionic polymer of the present invention is generally 0.005:1 to 10:1, 0.05:1 to 10:1, 0.5:1 to 10:1, 1:1 to 1:5, preferably 0.1:1 to 1:5, and most preferably 0.005:1 to 0.5:1, weight / weight, compared to the biomass loading.
[0152] The ratio of biomass to water used in the methods described herein depends on several factors, including, for example, the type of biomass and the amount of biomass. In some embodiments, the ratio of biomass to water and / or an organic solvent (e.g., an alcohol, an ether, a ketone, a deep eutectic solvent) used in the methods described herein is 1:100 to 1:1, preferably 1:50 to 1:10, or preferably 0.5:10 to 1.5:10, by weight / volume.
[0153] The preferred temperature profile for heating used in the methods described herein depends on the biomass starting material used and the desired monomer and oligomer mixture produced. Preferably, the heating temperature should be maintained at a maximum of 170°C, and in some embodiments maintained at a maximum of 150°C. In some embodiments, the heating temperature is 50°C to 170°C, or 80°C to 170°C, preferably 100°C to 150°C, or 100°C to 130°C. Preferably, for small-scale applications, heating is carried out in an autoclave reactor, which, after sealing, is heated for an appropriate reaction time and temperature.
[0154] In some embodiments, suitable reaction times in the methods described herein are, for example, 10 minutes to 10 hours, preferably 0.5 hours to 5 hours, or 0.5 hours to 3 hours, or 1 hour to 3 hours, depending on the type and amount of biomass.
[0155] The process for producing the prebiotic composition operates at moderate temperatures (generally below 150° C.), whereas prior art processes require temperatures above 150° C. In addition, the process for producing the prebiotic composition of the present invention provides fewer by-products, making it easier to recover the desired product.
[0156] Another aspect of the present invention provides a prebiotic composition obtained by the method for producing a prebiotic composition of the present invention.
[0157] In various embodiments, the prebiotic composition of the present invention includes at least one carbohydrate. This carbohydrate can be a bio-based compound. The benefit of carbohydrates can be to promote the growth of beneficial microorganisms in the body area by providing an energy source, thereby improving the balance of the symbiotic microbial community in the body area. In some embodiments, the at least one carbohydrate compound includes inulin, α-glucan oligosaccharides, fructooligosaccharides, isomaltooligosaccharides, xylooligosaccharides, arabinoxylo-oligosaccharides, β-glucans, transgalactooligosaccharides, manno-oligosaccharides, lactulose, xylitol, lactitol, trehalose or a combination thereof. The prebiotic composition of the present invention can also include hydrolyzed proteins and phenolic substances (e.g., ferulic acid).
[0158] In some embodiments, the prebiotic composition of the invention comprises (by weight %):
[0159] Total oligosaccharides: 50% to 70%
[0160] Protein and / or protein hydrolysate: 20% to 40%
[0161] Phenolic compounds (phenols): <1%
[0162] Minerals: <8%
[0163] ·Moisture: <10%
[0164] Wherein the oligosaccharide is selected from:
[0165] Glucose: 1% to 20% of total oligosaccharide weight
[0166] Xylose: 20% to 40% of total oligosaccharides by weight
[0167] Arabinose: 5% to 30% of total oligosaccharides by weight
[0168] And wherein the degree of polymerization (DP) of the oligosaccharide is distributed as follows:
[0169] DP1: 0% to 10%
[0170] DP2 to DP30:>80%.
[0171] A specific embodiment provides a prebiotic composition of the invention wherein the oligosaccharide comprises β-(1,4)-linked xylose units substituted with α-(1,2)arabinose or α-(1,3)arabinose or α-(1,2)arabinose and α-(1,3)arabinose to form linked glucose units of the (1,3)-(1,4)-β-D-glucan molecule.
[0172] Another specific embodiment provides a prebiotic composition of the invention, wherein the oligosaccharide comprises an arabinoxylo-oligosaccharide, the structure of which is linear and branched, preferably wherein at least one arabinose or xylose is located at the reducing end of the oligosaccharide backbone. The ratio between arabinose and xylose units in the oligosaccharide varies depending on the reaction conditions and the ionic polymer used. Thus, in one embodiment, in the prebiotic composition of the invention, the branched oligosaccharide comprises arabinose and xylose units, preferably wherein the arabinose / xylose ratio is 0.4-1.2, preferably the ratio is 0.4-1.0, preferably the ratio is 0.45-1.0, preferably the ratio is 0.5-0.9. In one embodiment of the prebiotic composition, the branched or linear oligosaccharide comprises xylose units and contains almost no arabinose groups.
[0173] In one embodiment of the prebiotic composition of the invention, the oligosaccharide comprises at least two β(1-4) glucose units linked together.
[0174] In one embodiment of the prebiotic composition of the invention, the oligosaccharide comprises at least two β(1-4) linked xylose units linked together.
[0175] In one embodiment of the prebiotic composition of the invention, the oligosaccharide comprises at least one branch consisting of a β(1-3) linked xylose unit or an α(1-3) linked arabinose unit attached to the main chain.
[0176] In one embodiment of the prebiotic composition of the invention, the oligosaccharide comprises a β(1-4) linked xylose unit linked to at least one α(1-2) arabinose unit.
[0177] In one embodiment of the prebiotic composition of the invention, the oligosaccharide comprises β(1-4) linked xylose units, wherein a mono-substituted xylose is linked to at least one α(1-2) arabinose unit and one α(1-3) arabinose unit.
[0178] In one embodiment of the prebiotic composition of the invention, the oligosaccharide comprises β(1-4) linked xylose units, wherein at least one disubstituted xylose is linked to one α(1-2) arabinose unit and one α(1-3) arabinose unit.
[0179] In one embodiment of the prebiotic composition of the invention, the oligosaccharide comprises β(1-4) linked xylose units, wherein at least one monosubstituted xylose having an α(1-3) arabinose unit and a disubstituted xylose having one α(1-2) arabinose unit and one α(1-3) arabinose unit are present.
[0180] In one embodiment of the prebiotic composition of the invention, the oligosaccharide comprises at least one trisaccharide in which xylose is linked via a (1-4) bond between two glucose units (Glcα(1-4)Xylα(1-4)Glc) or one arabinose and xylose unit (Araα(1-6)[Xylβ(1-4)]Glc).
[0181] In one embodiment of the prebiotic composition of the invention, the oligosaccharide comprises at least one branch consisting of a β(1-2) linked xylose unit or an α(1-3) linked arabinose unit attached to the main chain.
[0182] In one embodiment of the prebiotic composition of the invention, the oligosaccharide comprises at least one trisaccharide in which xylose is linked via a (1-4) bond between two glucose units (Glcα(1-4)Xylα(1-4)Glc) or one arabinose and xylose unit (Araα(1-6)[Xylβ(1-4)]Glc).
[0183] In some embodiments, the backbone of the prebiotic composition of the present invention consists of β-(1,4)-linked xylose residues. It may be substituted with arabinose residues, while hydroxycinnamic acid, ferulic acid and p-coumaric acid may be esterified on the arabinose residues.
[0184] In some embodiments, the backbone of the prebiotic composition of the present invention consists of β-(1,4)-linked xylose residues, which may be substituted with arabinose residues, while additional uronic acids or methylated uronic acids may be present thereon.
[0185] In some embodiments, the average molecular weight of the oligosaccharides and / or proteins in the prebiotic composition of the present invention is less than 10 kDa, preferably less than 7.5 kDa, preferably less than 5 kDa, preferably less than 4 kDa, preferably less than 2 kDa.
[0186] One advantage of the prebiotic composition of the present invention is that it does not cause turbidity when used in a cosmetic composition. Another advantage of the prebiotic composition of the present invention is that it has little or very light color, which does not color the cosmetic composition.
[0187] Another aspect of the present invention provides a topical cosmetic composition comprising:
[0188] - an effective amount of a prebiotic composition of the present invention, and
[0189] - at least one dermatologically acceptable carrier.
[0190] The topical cosmetic composition herein comprises an effective amount of a prebiotic composition of the present invention. The prebiotic composition may be present in an amount greater than 0.001%, 0.01%, 0.05%, 0.1%, 0.5%, 1%, 2%, 3%, 4%, or even greater than 5% by weight of the topical cosmetic composition. It may be desirable to limit the amount of the prebiotic composition in the topical cosmetic composition of the present invention to less than 25%, 20%, 15%, 10%, or even 5% by weight of the composition to avoid cosmetically undesirable properties (e.g., stickiness or poor spreadability). In certain embodiments, the prebiotic composition may be present in an amount of 0.1% to 10%, preferably 0.5% to 5%, and most preferably 0.001% to 5% by weight of the topical cosmetic composition.
[0191] In certain embodiments, the prebiotic composition may be present in an amount sufficient to increase the bacterial count of at least one skin commensal microorganism in vitro by at least 10% (e.g., 10% to 200% or more, 50% to 175%, 100% to 150%, or any value within these ranges). Additionally or alternatively, the prebiotic composition may be present in an amount sufficient to increase the bacterial count of at least two skin commensal microorganisms in vitro by at least 10% (e.g., 10% to 200%, 20% to 180%, 30% to 160%, 40% to 150%, 50% to 120%, or any value within these ranges). Furthermore, the prebiotic composition may be present in an amount sufficient to increase the bacterial count of at least three skin commensal microorganisms in vitro by at least 10% (e.g., 10% to 200% or more or any value within these ranges). In vitro bacterial counts may be determined according to a plate count assay described in more detail below.
[0192] The topical cosmetic composition of the present invention includes one or more dermatologically acceptable carriers. Such carriers may be selected from:
[0193] - Water and / or a water-miscible solvent. Suitable water-miscible solvents include monohydric alcohols, dihydric alcohols, polyhydric alcohols, glycerol, glycols, polyalkylene glycols such as polyethylene glycol, and mixtures thereof. When the topical cosmetic composition is in the form of an emulsion, water and / or a water-miscible solvent is typically combined with the water of the emulsion.
[0194] - One or more suitable oils. The oil may be a volatile or non-volatile oil. Volatile oils suitable for use in the present invention may have a viscosity of 0.5 to 5 centistokes (cSt) at 25°C. Volatile oils may be used to promote faster drying of the skin care composition after application to the skin. Non-volatile oils may be included to provide emollient and protective benefits to the skin.
[0195] - one or more suitable silicone oils (e.g. one or more polysiloxanes), and /
[0196] or hydrocarbon oils (e.g., linear, branched or cyclic alkanes and alkenes) and / or amides (suitable amides include N-acetyl-N-butylaminopropionate, N-lauroyl sarcosine isopropyl ester and N,N,-diethyltoluamide), and / or ethers (suitable examples of these ethers include PPG-14 butyl ether,
[0197] PPG-15 stearyl ether, dioctyl ether, dodecyl octyl ether and mixtures thereof).
[0198] - Emulsifiers. When the composition is provided in the form of an emulsion, or when immiscible materials are to be mixed, an emulsifier may be desirable.
[0199] - Structuring agents can be used to increase viscosity, thicken, solidify or provide a solid or crystalline structure to a topical cosmetic composition. Structuring agents are generally grouped based on solubility, dispersibility or phase compatibility. Examples of aqueous or water structuring agents include polymeric agents, natural or synthetic gums, polysaccharides, and the like. Other exemplary classes of polymeric structuring agents include, but are not limited to, carboxylic acid polymers, polyacrylamide polymers, sulfonated polymers, high molecular weight polyalkylene glycols or polyglycerols, copolymers thereof, hydrophobically modified derivatives thereof, and mixtures thereof.
[0200] The topical cosmetic composition of the present invention may optionally include ingredients for regulating and / or improving the condition of mammalian skin. Some non-limiting examples of such optional ingredients include vitamins (one or more water-soluble vitamins, such as vitamin B, vitamin C, vitamin D, vitamin K), peptides and peptide derivatives, sugar amines, sunscreen actives (or sunscreens) and / or ultraviolet light absorbers, humectants, moisturizers, skin conditioners, colorants (pigments, dyes, lakes, combinations of these substances, etc.), film-forming compositions, phytosterols, salicylic acid compounds, hexamidine, dialkanoyl hydroxyproline compounds, flavonoids, retinoid compounds, botanicals, N-acyl amino acid compounds, derivatives thereof, and combinations thereof.
[0201] The topical cosmetic composition of the present invention can be in any of a variety of forms known in the art, including, for example, emulsions, lotions, milks, liquids, solids, creams, gels, mousses, ointments, pastes, serums, sticks, sprays, tonics, aerosols, foams, pens, etc. The cosmetic composition can also be incorporated into shaving preparation products, including, for example, gels, foams, lotions, and creams, and includes both spray-type and non-spray-type forms. Other cosmetic compositions include antiperspirants, deodorants, and personal cleansing compositions, such as soaps and shampoos.
[0202] The topical cosmetic composition of the present invention can be prepared according to conventional methods for preparing such compositions known in the art. Such methods can include mixing ingredients in one or more steps to reach a relatively uniform state under conditions such as heating or not heating, cooling, applying vacuum, etc. For example, an emulsion can be prepared by first mixing the aqueous phase material separately from the fat phase material, and then the two phases are appropriately mixed to produce the desired continuous phase. In certain embodiments, compositions can be prepared to provide suitable stability (physical stability, chemical stability, light stability, etc.) and / or the delivery of active materials. The compositions can be provided in a package whose size is capable of storing a sufficient amount of the compositions required for the treatment period. The size, shape and design of the packaging can vary greatly.
[0203] Another aspect of the invention provides the use of a prebiotic composition of the invention or a topical composition of the invention for non-therapeutic treatment of the skin. In some embodiments of the invention, the non-therapeutic treatment is protection and / or regeneration of the skin. In other embodiments of the invention, the non-therapeutic treatment is protection and improvement of the condition and / or appearance of the skin. In other embodiments of the invention, the non-therapeutic treatment is maintenance of skin hydration. In other preferred embodiments, the non-therapeutic treatment is regeneration and / or protection of the skin, improvement of the condition and / or appearance of the skin, and maintenance of skin hydration.
[0204] In some embodiments, the present invention provides a method of non-therapeutic treatment of the skin, the method comprising applying to the skin an effective amount of a prebiotic composition of the present invention or a topical composition of the present invention. In preferred embodiments, the non-therapeutic treatment is regeneration and / or protection of the skin. In other preferred embodiments, the non-therapeutic treatment is improving the condition and / or appearance of the skin. In other preferred embodiments of the present invention, the non-therapeutic treatment is maintaining skin hydration. In other preferred embodiments, the non-therapeutic treatment is regeneration and / or protection of the skin, improving the condition and / or appearance of the skin, and maintaining skin hydration.
[0205] Another aspect of the present invention provides the use of the prebiotic composition of the present invention or the topical composition of the present invention for regulating the growth of at least one symbiotic bacteria (microorganism) of the skin. In a preferred embodiment, the regulation is to promote or enhance the growth of at least one symbiotic bacteria. In some embodiments, the symbiotic bacteria are selected from Propionibacterium acnes, Corynebacterium tuberculostearicum, Streptococcus mitis, Streptococcus oralis, Streptococcus pseudopneumoniae, Streptococcus sanguinis, Micrococcus luteus, Staphylococcus epidermidis, Staphylococcus capitis, Veillonella parvula. In a preferred embodiment, the symbiotic bacteria are Staphylococcus epidermidis.
[0206] Another aspect of the present invention provides a method for regulating the growth of at least one commensal bacteria (microorganism) on the skin, the method comprising applying to the skin an effective amount of a prebiotic composition of the present invention or a topical composition of the present invention. In some embodiments, the commensal bacteria are selected from Propionibacterium acnes, Corynebacterium tuberculosis, Streptococcus mitis, Streptococcus oralis, Streptococcus pseudopneumoniae, Streptococcus sanguinis, Micrococcus luteus, Staphylococcus epidermidis, Staphylococcus capitis, Veillonella parvum. In a preferred embodiment, the commensal bacteria is Staphylococcus epidermidis.
[0207] Another aspect of the present invention provides the use of the prebiotic composition of the present invention or the topical composition of the present invention for preventing dysbiosis. In a preferred embodiment, the present invention provides the use of the prebiotic composition of the present invention or the topical composition of the present invention for preventing dysbiosis on the outer surface of the human or animal body, preferably on the outer surface of the human or animal skin. In some embodiments, this use of the prebiotic composition of the present invention or the topical composition of the present invention is a non-therapeutic use.
[0208] Another aspect of the present invention provides a method for preventing dysbiosis, the method comprising applying to the skin an effective amount of a prebiotic composition of the present invention or a topical composition of the present invention. In a preferred embodiment, the present invention provides a method for preventing dysbiosis on the outer surface of a human or animal body, preferably on the outer surface of human or animal skin, the method comprising applying to the skin an effective amount of a prebiotic composition of the present invention or a topical composition of the present invention. In some embodiments, this use of a prebiotic composition of the present invention or a topical composition of the present invention is a non-therapeutic use.
[0209] Dysbiosis generally involves the loss of beneficial bacteria (microbes), such as commensal bacteria, and the proliferation of pathogenic bacteria (microbes).
[0210] Another aspect of the invention provides the use of a prebiotic composition of the invention or a topical composition of the invention for stimulating the immune skin system. In a preferred embodiment, stimulation of the immune skin system is obtained by increasing the growth and / or colonization of Staphylococcus epidermidis on the skin or commensal bacteria (microorganisms) on the skin. In some embodiments, stimulating the immune skin system provides enhanced immunity to the outer surface of the human or animal body (e.g., human or animal skin). In some embodiments, this use of a prebiotic composition of the invention or a topical composition of the invention is a non-therapeutic use.
[0211] Another aspect of the invention provides a method for stimulating the immune skin system, the method comprising applying an effective amount of a prebiotic composition of the invention or a topical composition of the invention to the skin. In a preferred embodiment, stimulation of the immune skin system is obtained by increasing the growth and / or colonization of Staphylococcus epidermidis on the skin or commensal bacteria (microorganisms) on the skin. In some embodiments, stimulating the immune skin system provides enhanced immunity to the outer surface of the human or animal body (e.g., human or animal skin). In some embodiments, this use of the prebiotic composition of the invention or the topical composition of the invention is a non-therapeutic use.
[0212] Prebiotic compositions of the present invention can be selectively utilized by microorganisms (bacteria) on and / or in the skin to provide health benefits, such as protection and / or regeneration of the skin and / or protection and improvement of the condition and / or appearance of the skin. This prebiotic composition can provide the following health benefits: selectively stimulate beneficial symbiotic microorganisms, competitively antagonize and damage the growth of opportunistic, undesirable or pathogenic microorganisms. This health benefit can include helping symbiotic microorganisms and beneficial microorganisms to breed on and / or in the skin. For example, in some embodiments, the prebiotic composition of the present invention can promote the growth of symbiotic bacteria Staphylococcus epidermidis (S.epidermidis) and / or other symbiotic bacteria. Health benefits can include protecting and promoting the balance and diversity of microbial populations on and / or in the skin. Another health benefit can include promoting, restoring, strengthening and maintaining skin defenses to resist the overgrowth or infection of harmful microorganisms, or resisting external toxic substances. This health benefit can include stimulating the keratinocytes in the skin to release antimicrobial peptides. Another health benefit may include increasing the skin's resistance to pathological conditions including, but not limited to, dermatitis, acne, rosacea, eczema, and premature aging. In addition, such prebiotic compositions may improve skin condition and / or appearance.
[0213] In some embodiments, by changing the parameters of the method for producing a prebiotic composition of the present invention, it is possible to obtain a prebiotic composition having only a prebiotic effect, or a prebiotic composition having both a prebiotic effect and an antipathogenic effect. The antipathogenic effect means that the composition inhibits the growth of pathogenic bacteria.
[0214] Colonization of the skin microbiota with Staphylococcus epidermidis can affect the immune function of the skin and / or reduce premature aging of the skin. S. epidermidis promotes the restoration of healthy skin, in part by preventing the colonization of the skin microbiota by pathogenic microorganisms. S. epidermidis has also been shown to affect host immunity by enhancing host immunity against S. aureus, activating mast cell-mediated immunity, suppressing uncontrolled inflammatory responses during wound healing, inducing the production of antimicrobial proteins in the skin, and stimulating the maturation of skin T cells. Therefore, S. epidermidis can work synergistically with the host defense system and endogenous AMPs to protect the skin. In addition, the microbiome can represent an environmental filter, as most agents that come into contact with and / or penetrate the skin also come into contact with the microbiota.
[0215] In other embodiments, the prebiotic composition of the present invention applied to the skin can increase the colonization of Staphylococcus epidermidis on the skin, thereby protecting the skin from premature aging and reducing signs of aging, such as reducing hyperpigmentation, wrinkles, and inflammation, and improving the adaptive capacity of the skin. The skin microbiome modulating composition can also protect the skin from oxidative damage from the environment. Oxidative damage from ultraviolet radiation from the sun and air pollution can cause harmful effects on human skin, including sunburn, immunosuppression, and premature aging, such as photoaging, which can be characterized in part by wrinkles, changes in pigmentation, and loss of skin color.
[0216] Without being limited by theory, it is believed that the health of the skin microbiome may be related to desired skin function or appearance, and / or may provide one or more skin care benefits. For example, the appearance, barrier function, moisture retention and / or other properties of the skin may be maintained or improved by maintaining or improving the health of one or more members of the skin microbiome. In some cases, if one or more specific areas of the skin exhibit undesirable function and / or appearance, it may be necessary to target maintenance or improvement to that specific area of the skin. For example, it may be necessary to target specific areas of the skin, such as the face (e.g., forehead, cheeks, and periorbital portions of the face), hands and / or forearms, which are more susceptible to damage due to exposure to the environment (e.g., UV radiation, wind, pollution, oxidation, irritants) than some other areas of the skin, and / or visible signs of intrinsic aging may occur.
[0217] The prebiotic compositions or topical cosmetic compositions disclosed herein may be suitable for use as topical skin care products or cosmetics that can be applied as part of a user's daily makeup or personal care regimen. Additionally or alternatively, the prebiotic compositions or topical cosmetic compositions herein may be used "as needed". In certain embodiments, a skin care product (such as a moisturizer, lotion, or ointment) comprising at least one dermatologically acceptable carrier and an effective amount of a prebiotic composition of the present invention may be topically applied to one or more target areas of a user's skin (e.g., face, forearms, hands, or portions of these areas) to provide skin care benefits or improve the health and / or appearance of the skin in the target area. In certain embodiments, the prebiotic compositions of the present invention may be incorporated into a makeup product (e.g., foundation) and applied to the user's face or portion thereof as part of a daily beauty regimen.
[0218] In certain embodiments, specific areas of the skin may be identified as being in need of skin care benefits that may be addressed using the prebiotic compositions of the present invention or the topical cosmetic compositions of the present invention. For example, facial areas (e.g., nose, cheeks, forehead, chin, around the eyes), the front and back of the neck, the tops of the hands, the tops of the forearms, the shoulders, and / or major body folds may be identified as being in need of treatment by the prebiotic compositions or topical cosmetic compositions of the present invention. Of course, it should be understood that the prebiotic compositions or topical cosmetic compositions disclosed herein may be applied to any part of the skin of the body (e.g., feet, legs, back, upper arms, torso, buttocks) to provide a cosmetic effect, and these parts of the skin may be identified as target areas.
[0219] The topical cosmetic composition of the present invention can be applied once or more per day as part of a user's regular beauty regimen (e.g., showering, applying makeup, applying moisturizer or other skin care or hair care products). The topical cosmetic composition of the present invention can be applied more than once a day, for example, once at the beginning of the day, once in the middle of the day, and / or once at the end of the day. In some cases, the topical cosmetic composition can be applied whenever the user applies or reapplies other cosmetic compositions such as lipstick or mascara. In some cases, the topical cosmetic composition of the present invention can be applied every other day, twice a week or three times a week, once a week, once every two weeks, or once a month as needed. When applying the topical cosmetic composition of the present invention, it may be best to allow at least a portion of the composition (e.g., the prebiotic portion) to exist on the user's skin for at least one hour (e.g., 1 to 24 hours, 2 to 20 hours, 4 to 16 hours, or 8 to 12 hours). In certain embodiments, when applying the composition, it may be best to allow at least a portion of the composition to exist on the skin for more than one day (e.g., 1 to 7 days, 2 to 6 days, 3 to 5 days, or even 4 days). In certain embodiments, it may be best to apply the topical cosmetic composition of the present invention at one or more of the aforementioned frequencies over at least two consecutive or non-consecutive application periods. For example, the composition can be applied once a day for 2, 3, 4, 5, 6, or 7 consecutive or non-consecutive days. In another example, the cosmetic composition of the present invention can be applied every other day for a month or longer.
[0220] Those skilled in the art will appreciate that the invention described herein may be subject to variations and modifications in addition to those specifically described. It should be understood that the invention includes all such variations and modifications without departing from its spirit or essential characteristics. The invention also includes all steps, features, compositions and compounds mentioned or indicated individually or collectively in this specification, as well as any two or more or any and all combinations of the steps or features. Therefore, the present disclosure should be considered to have been described in all aspects and is not restrictive, and the scope of the invention is represented by the appended claims, and all changes within the meaning and scope of equivalents should be included therein.
[0221] The foregoing description will be more fully understood with reference to the following examples. However, such examples are illustrative of methods of practicing the invention and are not intended to limit the application and scope of the invention.
[0222] Example
[0223] Preparation of beer spent grains (BSG) extract
[0224] Preparation of BSG-derived P1
[0225] 500 g of beer spent grains (BSG) (dry basis) suspended in 3.75 L of water was stirred at 140 ° C for 1 hour with the ionic polymer catalyst "IP1". After the reaction, the mixture was cooled to room temperature, filtered, and the liquid phase was dried using a spray dryer. The obtained dry powder product was analyzed and used for activity studies. P1 contained 57.9% oligosaccharides, of which the contents of arabinoxylan and glucan were 44.7% and 13.2%, respectively. See Table 1.
[0226] Preparation of BSG-derived P2
[0227] 267g BSG (dry basis) suspended in 4L water was stirred at 90°C for 1 hour. Afterwards, the mixture was cooled to room temperature, filtered, the solid phase was resuspended in 2.850L water together with "IP1", and stirred at 140°C for 1 hour. After the reaction, the mixture was cooled to room temperature, filtered, and the liquid phase was dried using a spray dryer. The obtained dry powder product P2 was analyzed and used for activity studies. P2 contains 62% oligosaccharides, of which the contents of arabinoxylan and glucan are 51% and 11%, respectively. See Table 1.
[0228] Preparation of BSG-derived P3
[0229] 200 g BSG (dry basis) suspended in 1.5 L water and 100 ml ethanol was stirred with ionic polymer catalyst "IP1" at 145°C for 1.5 hours. After the reaction, the mixture was cooled to room temperature, filtered, and the liquid phase was dried using a spray dryer. The obtained dry powder product was analyzed and used for activity studies. P3 contained 53.5% oligosaccharides, of which arabinoxylan and glucan contents were 38.3% and 15.2%, respectively. See Table 1.
[0230] Preparation of BSG-derived P4
[0231] 200 g of BSG (dry basis) suspended in 1.5 L of water was stirred at 140 ° C for 1 hour with the ionic polymer catalyst "IP1". After the reaction, the mixture was cooled to room temperature and filtered. A certain amount of bentonite was added to the filtrate, and the mixture was stirred at room temperature for 1 hour. Then, the mixture was filtered and the liquid phase was dried with a spray dryer. The obtained dry powder product was analyzed and used for activity studies. P4 contains 57% oligosaccharides, of which the contents of arabinoxylan and glucan are 41.4% and 15.6%, respectively. See Table 1.
[0232] Preparation of BSG-derived P5
[0233] 500 g of BSG (dry basis) suspended in 3.75 L of water was stirred at 140° C. for 1 hour with the ionic polymer catalyst "IP1". After the reaction, the mixture was cooled to room temperature, filtered, the solid residue in the presence of the catalyst was redispersed in water, and another hydrolysis cycle was performed. After cooling, the same type of operation was performed and the final hydrolysis cycle was completed. After cooling, the resulting mixture was filtered and the liquid phase was dried using a spray dryer. The obtained dry powder product was analyzed and used for activity studies. P5 contains 52.9% oligosaccharides, of which the contents of arabinoxylan and glucan are 48% and 4.9%, respectively. See Table 1.
[0234] Table 1:
[0235]
[0236] Preparation of BSG-derived P6
[0237] An ionic polymer IP-A5 was prepared, which was composed of a monomer of formula (I) and a monomer of formula VI:
[0238]
[0239] IP-A5 was used for the hydrolysis of spent barley.
[0240] 500 g of beer spent grains (BSG) (dry basis) suspended in 3.75 L of water was stirred at 130° C. for 1.5 hours with the ionic polymer catalyst "IP-A5". After the reaction, the mixture was cooled to room temperature, filtered, and the liquid phase was dried using a spray dryer. The resulting product contained 40.3% of oligosaccharides, of which arabinoxylan and glucan contents were 35.7% and 4.6%, respectively.
[0241] Preparation of BSG-derived P7
[0242] An ionic polymer IP-A6 was prepared, which was composed of a monomer of formula (I) and a monomer of formula (VI):
[0243]
[0244] IP-A6 was used for the hydrolysis of spent barley.
[0245] 500 g of beer spent grains (BSG) (dry basis) suspended in 3.75 L of water was stirred at 130° C. for 1.5 hours with the ionic polymer catalyst "IP-A6". After the reaction, the mixture was cooled to room temperature, filtered, and the liquid phase was dried using a spray dryer. The resulting product contained 61.5% of oligosaccharides, of which arabinoxylan and glucan contents were 46.8% and 14.7%, respectively.
[0246] Activity Study
[0247] A microbial screening study was conducted in liquid broth to evaluate the activity (bacterial growth) of five formulations (P1, P2, P3, P4, and P5) against two Staphylococcus species: (1) Staphylococcus aureus (MRSA) ATCC 33591 as a potential skin pathogen and (2) Staphylococcus epidermidis ATCC 12228 as a healthy skin commensal strain. To evaluate the potential and strain-specific antimicrobial or prebiotic activity against Staphylococci and to test the hypothesis that the ingredients may have a prebiotic effect (on S. epidermidis) while negatively affecting viability or growth rate (on S. aureus), the results of the experiment are presented below.
[0248] Prebiotics Verification
[0249] To evaluate the potential and strain-specific antimicrobial or prebiotic activity against Staphylococci: microdilution assays (viable counts on agar plates) were performed in liquid broth medium using 3 different concentrations (4%-2%-1% of each ingredient) in comparison with inulin and glucose as carbon source and prebiotic reference.
[0250] Each strain was inoculated in a nutrient-deficient medium supplemented with three concentrations of the test article and allowed to grow for 24 hours; then bacterial viability was measured by viable counts (CFU / mL) on agar plates at 4h and 24h, corresponding to the early exponential phase and stationary phase, respectively, to evaluate the effect of the test article on bacterial growth. Each treatment was repeated three times.
[0251] The growth rate was examined by viable count (CFU / mL) to quantify the number of residual viable cells present in the test culture, which was then expressed as a logarithmic value.
[0252] See the results in Table 2.
[0253] Table 2. Prebiotic efficacy of BSG derived products (ingredients) evaluated by microbial screening when two strains were used separately and expressed as logarithms (mean values).
[0254]
[0255] (1) First start date, (2) Second start date
[0256] Negative control (NC, medium only) and positive control PC (inulin 4% and glucose 4%) showed similar growth to the inoculum counts within 24 h, confirming bacterial viability and validating the test system.
[0257] For the BSG-derived ingredients tested, the observations revealed the following:
[0258] - Bold (in the S. epidermidis part) indicates the results when the number of CFU was higher than glucose 4% and inulin 4% (carbon source as prebiotic reference);
[0259] - Light grey indicates results when the difference between the number of CFU obtained in the presence of the test article (1% for P2 and 2% for P3) and the CFU obtained in the presence of glucose (4%) or inulin (4%) was greater than 0.5 Log (test article above control), which is considered the minimum significant increase defining a prebiotic effect (bacterial growth).
[0260] A slight effect was observed at 24 hours, but this may be related to the high concentration of bacteria and the fact that bacterial growth may have reached a stable phase. It should be noted that the bacterial viability measured at 4h and 24h corresponds to the early exponential phase and the stable phase, respectively. The stable phase (idiophase) is the phase in which the microorganism stops growing, which is usually due to growth limiting factors such as the exhaustion of essential nutrients; the stable phase is generated by a situation in which the growth rate and the death rate are equal (the number of new cells produced is limited by the growth factors, so the cell growth rate is equivalent to the cell death rate). After this phase, a decline phase may begin, in which the bacteria die due to lack of nutrients, which makes the interpretation of the quantification of viable bacterial growth at 24h not very reliable.
[0261] All BSG derived formulations (P1-P2-P3-P4-P5) showed the ability to control the growth of S. aureus (bacteriostatic effect). Specifically, these results show that: - The bold (in the S. aureus part) indicates the results when the number of CFU is lower than glucose 4% and inulin 4% (carbon source as prebiotic reference)
[0262] - Bold italics indicate results when the difference between the number of CFU obtained in the presence of the test article and the CFU obtained in the presence of glucose (4%) or inulin (4%) was greater than 0.5 Log (test article below control), which is considered to be the minimum significant reduction defining an antimicrobial effect (reduction in bacterial growth). A better antimicrobial effect was observed within 4 hours, since within 24 hours only P3 (all concentrations) and 4% of P2 and 4% of P1 showed a significant antimicrobial effect.
[0263] Anti-pathogen certification
[0264] Next, a series of experiments were performed aimed at testing the hypothesis that these ingredients might have different effects on bacterial species, and in particular that they might have a prebiotic effect on S. epidermidis while having a negative impact on the viability or growth rate of S. aureus.
[0265] The ingredients were diluted into minimal growth medium at the three required concentrations and added to a plate with a low level inoculum (10 2 ) in a mixture of the two Staphylococci (ratio 1:1) and allowed to grow for 24 h; then, at 4 and 24 h, the viability of each bacterium was measured by performing viable counts (CFU / mL) on Chromoselect agar plates (which can distinguish the two strains) to evaluate the effect on bacterial growth.
[0266] See the results in Table 3.
[0267] Table 3. Microbial screening to evaluate the prebiotic efficacy of BSG derived products (ingredients) when two strains were used simultaneously and expressed as logarithms (mean values).
[0268]
[0269] (1) First start date, (2) Second start date
[0270] Negative control (NC, medium only) growth within 4 h was not different from the inoculum counts, confirming bacterial viability and the validity of the test system.
[0271] All formulations (P1-P2-P3-P4-P5-A82) showed the ability to control bacterial growth (bacteriostatic effect) within 4 hours compared to the control group. Specifically, the results revealed the following:
[0272] - Bold (in the S. epidermidis section) indicates results when the number of CFU was higher than the negative control (medium only);
[0273] - Light grey represents the results when the difference between the number of CFU obtained in the presence of the test article (2% of P5 (after 2 h) and 4% of P4 (after 4 h)) and the CFU obtained in the negative control is greater than 0.5 Log (test article above control), which is considered the minimum significant increase that defines a prebiotic effect (bacterial growth);
[0274] - Bold (in the S. aureus section) indicates results when the number of CFU is lower than that of the negative control (medium only);
[0275] - Bold italics indicate results when the difference between the number of CFU obtained in the presence of the test article (all concentrations of P3 (after 2 h) and higher concentrations (4%) of P1, P2, P3 and P4 (after 4 h)) and the CFU obtained in the negative control is greater than 0.5 Log (test article below control), which is considered the minimum significant reduction defining an antimicrobial effect (reduction in bacterial growth). Taking both effects together, the prebiotic effect (increase in growth) for S. epidermidis
[0276] (increase of 0.71Log) and antimicrobial effect on Staphylococcus aureus (reduction in growth)
[0277] (0.56Log reduction), it can be concluded that the best effect is achieved after 4 hours of contact with 4% P4.
[0278] in conclusion
[0279] Potential antimicrobial activity against S. aureus and prebiotic effect against S. epidermidis: Considering that a CFU difference of more than 0.5 Log compared to both controls (4% inulin and 4% glucose) was considered significant to determine a prebiotic effect (increased bacterial growth) or an antimicrobial effect (reduced bacterial growth), the best and robust results are shown below:
[0280] - After 4 hours of contact with 1% P2;
[0281] - After 4 hours of contact with 2% P3.
[0282] Considering that differences of more than 0.5 Log compared to the negative control were considered significant to determine the prebiotic effect (increased bacterial growth) or the antimicrobial effect (reduced bacterial growth), contact with P4 at a concentration of 4% after 4 hours showed better results for both combined effects.
[0283] Reconstructed Human Epidermis (RHE) Test
[0284] The main objective of this study was to evaluate the potential efficacy of BSG-derived formulations in a more biologically relevant in vitro preclinical model based on colonized reconstructed human epidermis (RHE). The main focuses were:
[0285] I. Counteracting the adhesion and proliferation of Staphylococcus aureus. The rationale is based on the possibility that the ingredients may balance the inflammatory response caused by the bacteria, reducing its adhesion and growth on the RHE model (inhibition study);
[0286] II. Prebiotic effects of the three preparations on Staphylococcus epidermidis (prebiotic study). The rationale is based on the potential protection and biostimulation of the normal skin microbiota by the ingredients described;
[0287] III. Their biological impact on the germ-free RHE model The rationale is based on the potential for the ingredients to enhance or balance the innate immune response.
[0288] The following BSG-derived preparations were used in this study:
[0289] - For inhibition and composition-affecting effects: 1% P1, 2% P3, 4% P4;
[0290] - For prebiotic effect: 1% A 78, 2% P3, 1% P5.
[0291] SkinEthic @ Reconstruction of human epidermis 0.5cm 2 Is a reconstructed epidermis of normal human keratinocytes. Cells are grown on inert polycarbonate filters in chemically defined medium for 17 days. The model recapitulates epidermal morphology and has been well characterized. Good barrier function, batch reproducibility and low variability with respect to the permeability of probe molecules compared to human ex vivo models are described in the literature. RHE batches are tested for the presence of antibodies to HIV1 and HIV2, antibodies to Hepatitis C and the Hepatitis B antigen HBs. The absence of bacteria, fungi and mycoplasma on the donor-derived cells is confirmed. The maintenance medium is tested for sterility.
[0292] Instructions for preparation of bacterial suspension for RHE colonization
[0293] Two days before the test, bacterial strains (Staphylococcus aureus and Staphylococcus epidermidis) were inoculated onto culture media (BHI agar plates) and cultured at 37°C aerobic conditions for at least 24 h to obtain fresh cultures. On the day of colonization, the bacterial strains were resuspended in sterile saline solution in the desired concentration range. Each starting bacterial inoculum concentration was checked by spectrophotometric OD measurement and adjusted to obtain approximately 10 7 -10 8 UFC / mL (OD = 0.1); then diluted 10-fold to obtain 10 3 -10 4 The final range of UFC / tissue concentrations and 10 for prebiotic studies 4 -10 5 Final range concentration of UFC / tissue. Starting inoculum levels were also confirmed by serial ten-fold dilutions and viable counts on agar plates (BHI).
[0294] Description of treatment and colonization procedures
[0295] For inhibition and prebiotic studies, apical parts of RHE (applied directly on the tissue surface) were pretreated twice (50 μL and 30 μL overnight and 1 h, respectively, before colonization) and incubated at 37°C (with 5% CO2) until colonization. Pretreated RHE specifically used for inhibition and prebiotic studies were colonized with 30 μL of previously obtained bacterial suspension (Staphylococcus aureus for inhibition studies and Staphylococcus epidermidis for prebiotic studies, respectively) and incubated at 37°C (with 5% CO2) to the desired time point (24 h). Apical parts of sterile RHE (not colonized) (applied directly on the tissue surface) were pretreated twice (50 μL and 30 μL overnight and 1 h, respectively) and incubated at 37°C (with 5% CO2) to the desired time point (24 h).
[0296] At the end of the time points, apical remnants and tissues were recovered and homogenized before analysis. For inhibition studies and prebiotic studies: CFU and qRT-PCR (gene expression) for TLR-2, b-defensin 2, NOD-2 were performed. It is known that:
[0297] оTLR2 receptor is involved in innate immunity. It recognizes pathogen antigens and activates innate immunity by stimulating NF-kB;
[0298] оDEFB2 is induced by inflammatory stimuli and opportunistic pathogens, supporting the hypothesis that this peptide contributes to a dynamic host defense system;
[0299] оNOD-2 plays an important role in immune system function. In certain types of immune system cells, it helps protect the body against foreign invaders, such as bacteria and viruses. When triggered by specific substances produced by bacteria, the NOD2 protein activates NF-kB. It also plays a role in autophagy.
[0300] See the results in Table 4.
[0301] Table 4. Viable counts after 2 days of inhibition study using the RHE model
[0302]
[0303] The colonization control (CNZ) showed growth exceeding the inoculum, confirming bacterial viability and the validity of the test system.
[0304] The reference control (REF, Chlorexidine) showed no bacterial growth, confirming the susceptibility of the bacteria to the antimicrobial agent.
[0305] Formulation P3 at 2% and formulation P4 at 4% showed the ability to reduce bacterial growth compared to the colonized control. Specifically, the results showed that:
[0306] - Bold indicates results when the number of CFU was lower than the colonization control;
[0307] - Bold italics indicate results when the difference between the number of CFU obtained in the presence of the test article (P3 and P4) and the number of CFU obtained in the colonization control is greater than 0.5 Log (test article is lower than control), which is considered the minimum significant reduction defining an antimicrobial effect (reduction in bacterial growth).
[0308] based on Figure 1 Data shown, DEFB2 was upregulated in all series except NC (negative control): antimicrobial proteins are expressed when epidermal cells are stimulated by contact with microorganisms, and antimicrobial proteins are dynamic components of the local innate defense system of the skin; the expression of antimicrobial proteins in RHE treated with BSG-derived components suggests that these components may have the role of inducing major innate immune protection against infection (J.-M. Schroder, J. Harder. Molecules in focus human beta-defensin-2. Int. J. Biochem. Cell Biol., 31 (1999), pp. 645-651; P. Zanger, J. Holzer, R. Schleucher, H. Scherbaum, B. Schittek and S. Gabrysch. Severity of Staphylococcus aureus Infection of the Skin Is Associated with Inducibility of Human β-Defensin 3but Not Human β-Defensin2. Infection and Immunity Vol.78,No.7(2010),pp 3112-3117).
[0309] No gene regulation of NOD-2 was observed in all series, suggesting that the biological mechanism by which the BSG-derived formulation exerts its effects is not based on a pro-inflammatory NfkB-dependent pathway.
[0310] TRL-2 was upregulated only in the presence of the test article (4% P4): The protein encoded by this gene is a member of the Toll-like receptor (TLR) family and plays an important role in pathogen recognition and innate immune activation. It is a cell surface protein that can form heterodimers with other TLR family members to recognize molecules derived from microorganisms.
[0311] based on Figure 2The data shown in , DEFB2 was upregulated in all series except NC (negative control) and colonized control (CNZ): antimicrobial proteins are expressed when epidermal cells are stimulated by contact with microorganisms and are dynamic components of the local innate defense system of the skin; the expression of antimicrobial proteins in RHE treated with BSG-derived components suggests that these components may have the role of inducing a major innate immune protection against infections, as already observed in the case of S. aureus.
[0312] No gene regulation of NOD-2 was observed in all series, suggesting that the biological mechanism by which BSG-derived components exert their effects is not based on a pro-inflammatory NfkB-dependent pathway.
[0313] TLR-2 was not significantly expressed in any sample (should be clarified during PCT)
[0314] in conclusion
[0315] Staphylococcus aureus growth inhibition study:
[0316] Based on the results obtained by viable counts of the apical fraction and the homogenate fraction (pretreated) after 2 days, it can be said that P3 at a concentration of 2% after 2 days of pretreatment and P4 at a concentration of 4% after 2 days of pretreatment showed the best and robust results compared to the colonization series (CNZ). The inhibition of S. aureus growth was confirmed by the results of gene expression data on colonized RHE, where DEFB2, as an antimicrobial protein involved in the innate immune response, was upregulated in the presence of the tested ingredients. P4 at 4% induced a significant upregulation of the TRL-2 gene.
[0317] Prebiotic Research:
[0318] All three BSG-derived preparations confirmed the upregulation of defensin β2, a gene responsible for innate immune activation and enhanced antimicrobial properties, without activating pro-inflammatory pathways based on NOD-2 and TLR-2 genes.
Claims
1. A method for producing a prebiotic composition, the method comprising the following steps: a) providing biomass; b) optionally, determining the content of lipids, proteins and / or carbohydrates in the biomass; c) optionally, pretreating the biomass, wherein the optional pretreatment is hot water pretreatment at about 90° C.; d) optionally, removing lipids and / or proteins from the biomass; e) contacting the biomass with a catalyst in the presence of water and / or an organic solvent to form a reaction mixture, wherein the catalyst is an ionic polymer or a combination of ionic polymers, an ionic polymer network, a solid supported ionic polymer and / or a polymer membrane doped with an ionic polymer; f) heating the reaction mixture to 100° C. to 150° C. and degrading the biomass in the reaction mixture to produce a liquid phase and a solid phase, wherein the liquid phase comprises the prebiotic composition and the solid phase comprises residual biomass; g) cooling the reaction mixture to room temperature; h) separating at least a portion of the liquid phase from the solid phase; i) optionally, adding one or more compounds selected from bentonite, charcoal, zeolite, amorphous silica and / or ion exchange solvents to the separated liquid phase; and j) recovering the prebiotic composition from the separated liquid phase; Wherein the ionic polymer (IP) is composed of monomers of formula I or composed of a first monomer of formula I and at least one second monomer The second monomer is selected from: in n and m are independently selected from 1, 2, 3, 4, 5, 6; z and w are independently selected from 0, 1, 2, 3; Z1, Z2 and Z3 are each independently selected from the following cations: R1, R2, R3, R4, R5, R6 and R7 are each independently selected from a bond, H, C1-C6 alkyl, C1-C6 allyl, -CH2-(CH2)pO-(CH2)q-CH3, C1-C6 alkoxy, C1-C6 alkoxyalkyl, benzyl, -SO3H, -(CH2)q-SO3H, provided that two of R1, R2, R3, R4, R5, R6 and R7 are each a bond; p and q are independently selected from 0, 1, 2, 3, 4, 5, 6; L is an optional linker and, if present, each occurrence of L is independently selected from H, substituted or unsubstituted C1-C 20 Alkylene, C1-C 20 Alkenylene, C1-C 20 Alkyne and substituted or unsubstituted C5-C 10 Aryl, wherein the substituent is selected from H, -SO3H, -COOH, -[P(=O)(OH)2], -O-SO3H, -O-COOH, -O-[P(=O)(OH)2]; A is an optional acidic group and, if present, is independently selected at each occurrence from H, -SO3H, -COOH, -[P(=O)(OH)2], -O-SO3H, -O-COOH, -O-[P(=O)(OH)2], -CH2-COOH, provided that when z and w are 0, A is present in Formula IV; X - Selected from F - , Cl - Br - ,I - 、ClO4 - 、BF4 - PF6 - 、AsF6 - 、SbF6 - 、NO2 - 、NO3 - 、HSO4 - 、SO4 2- PO4 3- 、HPO4 2- CF3CO2 - CF3CO3 - 、CO3 2- CF3SO3 - 、C1-C6 carboxylate、CN - 、SCN - 、OCN - 、CNO - 、N3 - , tosylate, methanesulfonate, trifluoromethanesulfonate, trifluoroethanesulfonate, bis-trifluoromethanesulfonamido, docusate, ditoluenesulfonate; Ra is C1-C 24 alkyl; Rb and Rc are each independently selected from H and CH3, or are absent; Rd is C1-C 24 Alkylene or C1-C 24 Alkyl, optionally C1-C 24 Alkyl substitution; Re and Rf are each independently C1-C 24 alkyl; Y is N or O, provided that when Y is O, Rc is absent; R is selected from C1-C 24 Alkyl and C5-C 10 aryl, or absent; wherein the ionic polymer network comprises one or more ionic polymers (IPs) that are cross-linked; wherein the solid support has at least one surface comprising the one or more ionic polymers (IPs) or the ionic polymer network; wherein the polymer membrane incorporates the one or more ionic polymers (IP) or the ionic polymer network.
2. The method according to claim 1, wherein in the ionic polymer (IP), Z1, Z2 and Z3 are cations each independently selected from the following:
3. The method according to claim 1 or 2, wherein the second monomer of formula VI is 4. The method according to claim 1, wherein the ionic polymer (IP) is 5. The method according to any one of claims 1 to 4, wherein the biomass is spent brewery grains.
6. A prebiotic composition obtained by the method of any one of claims 1 to 5.
7. A topical cosmetic composition comprising: ● an effective amount of the prebiotic composition of claim 6, and - At least one dermatologically acceptable carrier.
8. Use of a prebiotic composition according to claim 6 or a topical composition according to claim 7 for non-therapeutic treatment of the skin.
9. Use according to claim 8, wherein the non-therapeutic treatment is protection and / or regeneration of the skin.
10. Use according to claim 8, wherein the non-therapeutic treatment is to protect and improve the condition and / or appearance of the skin.
11. The use according to claim 8, wherein the non-therapeutic treatment is maintaining the hydration of the skin.
12. Use of the prebiotic composition of claim 6 or the topical composition of claim 7 for modulating the growth of at least one commensal bacteria of the skin, the method comprising applying to the skin an effective amount of the prebiotic composition of claim 6 or the topical composition of claim 7.
13. The use according to claim 12, wherein the commensal bacteria are selected from Propionibacterium acnes, Corynebacterium tuberculostearicum, Streptococcus mitis, Streptococcus oralis, Streptococcus pseudopneumoniae, Streptococcus sanguinis, Micrococcus luteus, Staphylococcus epidermidis, Staphylococcus capitis, Veillonella parvula.
14. Use of the prebiotic composition of claim 6 or the topical composition of claim 7 for preventing dysbiosis.
15. Use of the prebiotic composition according to claim 6 or the topical composition according to claim 7 for stimulating the immune skin system.
